+Vote!
24/7 Wall St. (Free subscription) | yesterday
These are some of the top analyst Upgrades and positive calls we are seeing early this Friday morning: Boston Scientific (BSX) Started as Outperform at Piper... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
+Vote!
GadBall.com (Free subscription) | 07/24/2008
Senior Accounts Payable Specialist - Natick Corporate Headquarters. Take the next step in your career at Boston Scientific... Delivering on the promise of medical innovation begins at Boston Scientific! By delivering innovative products that help clinicians improve the lives of patients every single day, Boston Scientific makes a profound impact on the quality of medical care around the world. Join...
+Vote!
Boston Globe (Free subscription) | 07/22/2008
Shares of Boston Scientific Corp. fell Tuesday after the medical device maker reported its earnings fell 15 percent in the second quarter due to lower sales and charges from acquisitions and restructuring.
+Vote!
Rock The Truth (Free subscription) | 07/22/2008
The UP is LITERAL!! They all STILL MADE BOODLES of $$$!!!! Did you, American? Remember NET = PROFIT! "Boston Scientific.... Net income fell to $98 million. Revenue was $2.02 billion. Bank of America Corp... Second-quarter net income $3.41 billion. Revenue was a record $20.6 billion Apple Inc. reported a net income climbed to $1.07 billion American Express Co.... profit from continuing operations was...
+Vote!
Law Blog - WSJ.com (Free subscription) | 07/22/2008
Boston Scientific's profit fell 15% amid slumping sales of drug-coated stents. The medical-device maker issued a rosy third-quarter outlook, but shares were down after hours.
2Vote!
New York Times (Free subscription) | 07/22/2008
The medical device maker said on Monday that its second-quarter was hurt by acquisition, restructuring and other charges.
+Vote!
Boston Globe (Free subscription) | 07/22/2008
Medical device maker Boston Scientific Corp. said Monday it expects third-quarter adjusted earnings between 14 and 19 cents per share on revenue between $1.95 billion and $2.06 billion.
+Vote!
The Minneapolis/St. Paul Business Journal (Free subscription) | 07/22/2008
Charges for restructuring and divestments hurt Boston Scientific Corp.’s quarterly earnings, though the med-tech company saw an uptick in cardiac-product sales. (BSX)
+Vote!
Market Watch (Free subscription) | 07/21/2008
Boston Scientific says second-quarter net income dipped along with sales, as the company struggles to deal with lower sales of its trademark stents.
+Vote!
Boston Globe (Free subscription) | 07/21/2008
Medical device maker Boston Scientific Corp. said Monday its second-quarter profit declined, hurt by acquisition, restructuring and other charges, as revenue inched lower.
+Vote!
Market Watch (Free subscription) | 07/21/2008
LOS ANGELES (MarketWatch) -- Boston Scientific said Monday that second-quarter net income was $98 million, or 7 cents a share, compared with the $115 million, or 8 cents a share, for the same period a year ago. Sales for the Boston-based medical device maker were $2.02 billion vs. last year's $2.07 billion. The company said results were adversely impacted by various charges, and it would have reported...
+Vote!
PR News Wire (Free subscription) | 07/21/2008
NATICK, Mass., July 21 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: ) today announced financial results for the second
quarter ended June 30, 2008, as well as guidance for net sales and earnings
per share (EPS) for the third quarter of 2008.
Second quarter highlights:
-- Achieved net sales of $2.024 billion
-- Reported adjusted EPS of $0.20, an increase of 25 percent over prior
year
...
+Vote!
Market Wire - Investment Opinion (Free subscription) | 07/21/2008
LONDON (MARKET WIRE) MaybachFinancial.com is one of the fastest growing independent and unbiased research firms in the world. Through our numerous partnerships with many of the top investment minds in the world, we provide research on companies making a move in the markets. Investors seeking genuine analyst opinions on their investments for Boston Scientific Corporation (NYSE: BSX), UnitedHealth Group...